{"protocolSection":{"identificationModule":{"nctId":"NCT06073587","orgStudyIdInfo":{"id":"ION-682884-CS2-Scintigraphy"},"secondaryIdInfos":[{"id":"2019-002835-27","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Ionis Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"The CARDIO-TTRansform Scintigraphy Sub-study","officialTitle":"CARDIO-TTRansform ION-682884-CS2-Scintigraphy Sub-study"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-04-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-10-04","studyFirstSubmitQcDate":"2023-10-04","studyFirstPostDateStruct":{"date":"2023-10-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-25","lastUpdatePostDateStruct":{"date":"2025-11-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"AstraZeneca","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.","detailedDescription":"Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and have had a baseline scintigraphy scan will be offered the opportunity to participate in this sub-study which involves optional scintigraphy scans."},"conditionsModule":{"conditions":["Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)"],"keywords":["TTR","Amyloidosis","Cardiomyopathy"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ION-682884-CS2 Scintigraphy Subset","description":"Participants randomized in ION-682884-CS2 (NCT04136171) study to receive either eplontersen or placebo with baseline scintigraphy scan with planar and single-photon emission computerized tomography (SPECT) or SPECT with computed tomography (SPECT/CT) images will undergo an optional scintigraphy scan at Weeks 25 or 37, Week 97, and an additional scan at Week 140.","interventionNames":["Diagnostic Test: Scintigraphy scan"]}],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"Scintigraphy scan","description":"Scans will be performed as specified in the arm description.","armGroupLabels":["ION-682884-CS2 Scintigraphy Subset"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Changes From Baseline in Perugini Grading Score From Scintigraphy Scan Images at Week 140","description":"The Perugini grading scale visually compares tracer uptake in the myocardium and ribs following injection of the bone tracers (99mTc-DPD, 99mTc-Pyrophosphate \\[PYP\\], or 99mTc-HMDP). The scale includes 4 grade classifications: Grade 0- no cardiac uptake and normal rib uptake, Grade 1- cardiac uptake which is less than rib uptake, Grade 2- cardiac uptake with intensity similar rib uptake, and Grade 3- cardiac uptake greater than rib uptake with mild or absent rib uptake. Visual scores of 2 or greater are classified as ATTR-positive and less than 2 are interpreted as ATTR-negative.","timeFrame":"Baseline up to Week 140"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have been properly randomized into the ION-682884-CS2 study (NCT04136171) and should have had a baseline scintigraphy scan (99mTc-DPD, 99mTc- PYP, and 99mTc-HMDP) within 12 months prior to screening for ION-682884-CS2 with planar and SPECT or SPECT/CT images that can be read by the central reader.\n\nExclusion criteria:\n\n* Must not meet any of the exclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).\n* Must not have weight or body girth that exceeds the limits of the equipment specifications.\n* Should not have any previously reported hypersensitivity reaction to Technetium-99m.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and who signed informed consent for the Scintigraphy sub-study will participate in this sub-study.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Columbia University Irving Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Cleveland Clinic Main Campus","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Oregon Health and Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Hospital Universitario Puerta de Hierro","city":"Majadahonda","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}}]},"referencesModule":{"seeAlsoLinks":[{"label":"CARDIO-TTRansform Website","url":"https://www.cardio-ttransform.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D000686","term":"Amyloidosis"},{"id":"D009202","term":"Cardiomyopathies"}],"ancestors":[{"id":"D057165","term":"Proteostasis Deficiencies"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D006331","term":"Heart Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000076665","term":"Ventilation-Perfusion Scan"}],"ancestors":[{"id":"D011877","term":"Radionuclide Imaging"},{"id":"D003952","term":"Diagnostic Imaging"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D003947","term":"Diagnostic Techniques, Radioisotope"},{"id":"D012129","term":"Respiratory Function Tests"},{"id":"D003948","term":"Diagnostic Techniques, Respiratory System"}]}},"hasResults":false}